New Delhi, April 11 -- Siddharth Mittal, CEO and Managing Director of Biocon Limited, on Friday questioned who would pay the price to shift their establishments to the US where pharma manufacturing costs are higher than in India and China.

"I think we all know that manufacturing for all segments moved to China, which was a cost arbitrage over decades. And now you're trying to reverse it. So, there's a price to pay," Siddharth Mittal said, speaking at the Carnegie Global Technology Summit.

"And in our industry, I'll give you an example, that if a drug in is made at X price in China, it's 1.25 to 1.3 X in India. And the analysis we have done is if we have to do the same thing in the US, it's going to be 2X. So, who's going to pay the pric...